Related Experiment Video

Updated: Jun 11, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

MEFV E148Q polymorphism is associated with Henoch-Schönlein purpura in Chinese children

Xuelian He1, Hao Lu, Shixiu Kang

  • 1Wuhan Children's Hospital, No. 100 Hongkong Rd, Jiangan District, Wuhan, People's Republic of China, 430016. hxljm07@hotmail.com

Pediatric Nephrology (Berlin, Germany)
|July 6, 2010
PubMed

Insights

Genetic variants in the MEFV gene, specifically the E148Q polymorphism, are linked to Henoch-Schönlein purpura (HSP) susceptibility and joint involvement. This finding sheds light on the genetic factors contributing to this inflammatory disease.

Area of Science:

  • Genetics
  • Immunology
  • Rheumatology

Background:

  • Henoch-Schönlein purpura (HSP) is a multifactorial inflammatory condition with unknown pathogenesis.
  • Pyrin, encoded by the MEFV gene, is a key inflammasome component influencing immune gene expression.

Purpose of the Study:

  • To investigate the association between MEFV genetic variants and susceptibility to HSP.
  • To explore the role of these variants in the clinical outcomes of HSP patients.

Main Methods:

  • Case-control study involving 78 HSP patients and 189 controls in China.
  • Genotyping of MEFV gene polymorphisms, including E148Q, P369S, M694V, and M680I.

Main Results:

  • A significant association was found between the MEFV E148Q polymorphism and HSP susceptibility (OR 2.76, P=0.0001).
  • The E148Q C allele correlated with joint involvement (P=0.014) but not HSP nephritis (P=0.1).
  • Higher clinical scores were observed in patients with the CC genotype compared to CG or GG genotypes (P=0.011).

Conclusions:

  • The MEFV E148Q polymorphism may be a contributing genetic factor for HSP susceptibility.
  • E148Q variants are associated with HSP-related joint syndromes, suggesting a role in disease phenotype.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate10:05

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

Published on: January 17, 2018

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...